Fagron N.V.
ARSUF
Other OTC27.90
USD
+1.37
- -
ISIN
BE0003874915
Return %
Stock
S&P500
1Y
10.71
18.85
3Y
55.69
64.56
5Y
33.17
71.64
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Rafael Padilla
- Full Time Employees
- 3,828
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Venecoweg 20A Nazareth VL Belgium 9810
- IPO Date
- Feb 21, 2017
- Website
- fagron.com
- Similar Companies
- Business
- Fagron NV (ARSUF) is a leading global pharmaceutical compounding company that specializes in delivering personalized medicine solutions to hospitals, pharmacies, clinics, and patients worldwide. The company operates through three core segments: Essentials, offering pharmaceutical raw materials, compounding equipment, packaging, and supplies; Brands, developing innovative semi-finished products, pharmaceutical-grade vehicles, and formulations such as Pentravan transdermal bases and SyrSpend oral suspending vehicles; and Compounding Services, providing sterile and non-sterile ready-to-use compounded medications tailored to patient needs in facilities across Europe, North America, Latin America, and South Africa. Founded in 1990 and headquartered in Nazareth, Belgium, with operational headquarters in Rotterdam, Netherlands, Fagron serves over 150,000 customers in more than 30 countries across Europe, Africa, the Americas, Asia, and the Pacific. Fagron targets healthcare professionals and institutions, focusing on optimizing compounding processes to expand therapeutic options, particularly in areas like hormone replacement therapy, dermatology, health and wellness, neuropathic pain management, and hospital pharmacy needs. Its product portfolio emphasizes high-quality, GMP-certified solutions, including vertically integrated plastic packaging through recent enhancements and specialized outsourcing for pharmacies facing capacity constraints. In the past two years, Fagron has pursued an aggressive acquisition strategy as a disciplined serial acquirer, completing 10 deals in 2025 alone to strengthen its global leadership; notable transactions include CareFirst Specialty Pharmacy in New Jersey, USA, a 503A compounder focused on non-sterile health and wellness products, and Injeplast in São Paulo, Brazil, a GMP-certified plastic packaging producer, both announced in January 2025 with a combined enterprise value of approximately €30 million. Further recent acquisitions encompass University Compounding Pharmacy (UCP) in North America in September 2025, books of business from Amara in Poland and Magilab in Hungary in November 2025 to bolster EMEA hospital pharmacy presence, and the closure of EuroOTC in early 2025, alongside securing a new U.S. dollar credit facility for North American growth and obtaining shipping licenses for all 503B facilities to California. These moves, financed through internal resources and aligned with group EBITDA margins, support organic revenue expansion in prevention, lifestyle, and dynamic markets while enhancing operational scale and product diversification.
Fagron shareholders approve all proposed resolutions at the General Meetings
Fagron NV (ARSUF) Q1 2026 Sales/Trading Call Transcript
Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026
Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth
Fagron increases share capital through exercise subscription rights
Fagron NV (ARSUF) Q4 2025 Earnings Call Transcript
Fagron NV (ARSUF) Q3 2025 Sales Call Transcript
Fagron: Recent Capital Markets Day Confirms Upside Potential
Fagron: FDA Warning Letter Creates New Entry Opportunity
Fagron NV (ARSUF) Q2 2023 Earnings Call Transcript